Low event rates and short TTRs with warfarin were notable, and questions persist as to which patients truly need OAC.

Edoxaban, an oral anticoagulant, was equally or more effective than warfarin in reducing the risk of stroke and blood clots ...

Japanese researchers say they have found a pill that works as well as existing medication to prevent blood clots after heart ...

Edoxaban, an oral anticoagulant, was equally or more effective than warfarin in reducing the risk of stroke and blood clots ...

The Annals of Pharmacotherapy. 2008;42(6):790-805.

In patients with protein C and protein S deficiency, when warfarin therapy is started there is a more rapid fall in concentration of protein C (antigen and activity) than the other vitamin K ...

Edoxaban, a medication taken orally to prevent blood clots from forming, was found to be as effective and safe for stroke and ...

Edoxaban, a medication taken orally to prevent blood clots from forming, was found to be as effective and safe for stroke and ...

Edoxaban, an oral anticoagulant, was equally or more effective than warfarin in reducing the risk of stroke and blood clots for patients after heart valve replacement surgery, according to preliminary ...

Edoxaban (Savaysa) appeared at least on par with warfarin for 12-week thromboembolic prophylaxis after bioprosthetic valve ...

DOACs only and warfarin only are more likely to be prescribed to Medicare beneficiaries seeing clinicians in rural areas compared with urban areas.

Cadrenal aims to develop a better VKA blood thinner for these warfarin-dependent patients. Cadrenal Therapeutics, Inc. is a biopharmaceutical company focused on developing tecarfarin, a clinical-stage ...